Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

DB Alex Brown: Lowering Titan Pharmaceutical to 'Buy'


DB Alex Brown downgraded Titan Pharmaceutical (TTP) to buy from strong buy.

Analyst Dennis Harp says Novartis is conducting additional clinical trails on once-daily dosing of Zomaril prior to filing; Novartis expects filing for approval by year-end 2002, launch in early 2004. Harp believes the near-term dearth of

additional information on Zomaril will place downward pressure on Titan's shares, hence, he's now less bullish on stock at this time.

Nonetheless, Harp remains highly confident Zomaril could achieve sales of $750 million by 2005, and believes Titan has sufficient reserves to reach profitability. He cut the $53 12-month target to $29.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus